HER2- Breast Cancer

PCE

English - June 30, 2022 12:00 - 20 minutes - 19.3 MB - ★★★★ - 6 ratings
Courses Education Science Life Sciences app education np education podcasts for credit app medicine pa education np medicine pa medicine ce podcasts app podcasts cme podcasts Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: An Update from ASCO 2022

Next Episode: ASCO 2022: Advances in CLL/SLL

In this episode, Julia LaBarbera, MSN, RN, AGACNP-BC, discusses the latest evidence and guidance on how advanced practice providers can optimize patient outcomes with CDK4/6 inhibitors for HR+/HER2- breast cancer. Topics include:

An overview of the monarchE study leading to FDA approval of adjuvant abemaciclibKey trial data on abemaciclib, palbociclib, and ribociclib for metastatic HR+/HER2- breast cancerManaging adverse events associated with CDK4/6 inhibitorsPromoting adherence to oral therapy

Presenter:

Julia LaBarbera, MSN, RN, AGACNP-BC
Nurse Practitioner
Division of Hematology/Oncology
Department of Medicine
University of California, Los Angeles
Santa Monica, California

Link to full program:
PCE.is/Onc22